Tag: apixaban market demand

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

 

What is the Expected Growth Rate of the Apixaban Market from 2024 to 2033?
The apixaban market has experienced strong growth, anticipated to rise from $2.69 billion in 2023 to $2.92 billion in 2024, with a CAGR of 8.7%. This growth is driven by an increased incidence of atrial fibrillation, an aging population, regulatory approvals, favorable clinical outcomes, and a shift from warfarin to NOACs.

The apixaban market is expected to see strong growth, reaching $4.12 billion by 2028, with a CAGR of 9.0%. This growth is driven by the incidence of cardiovascular diseases, increased awareness, and an aging population. Key trends include advancements in drug delivery, increased research, and digital health innovations.

Claim Your Free Sample of the Global Apixaban Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=15979&type=smp

What Key Factors Are Fueling the Growth of the Apixaban Market?
The increasing incidence of cardiovascular disease is expected to propel the apixaban market. Cardiovascular disease includes various heart and blood vessel conditions, driven by unhealthy lifestyles and aging populations. Apixaban helps manage these diseases by reducing blood clot risks. For instance, the American Heart Association reported 931,578 cardiovascular disease-related deaths in 2023, an increase from 2022. Therefore, the rise in cardiovascular diseases is driving the apixaban market.

What Are the Major Segments of the Apixaban Market?
1) By Dosage Form: Capsule, Tablets
2) By Application: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

What New Trends Are Transforming the Apixaban Market?
Major companies in the apixaban market are focusing on developing generic anticoagulants to increase affordability and accessibility. In October 2022, Tiefenbacher Pharmaceuticals, a Germany-based healthcare company, introduced a generic version of Apixaban in Canada for stroke prevention and thrombotic disorder treatments.

Order Now for Fast Delivery of Your Apixaban Market Report!
https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report

Which Regions Are Driving Growth in the Apixaban Market?
North America was the largest region in the apixaban market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apixaban market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Apixaban Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the apixaban market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Apixaban Market Include

1. Apixaban Market Executive Summary
2. Apixaban Market Segments
3. Apixaban Market Size And Template Market Growth Rate
4. Key Apixaban Market Trends
5. Major Apixaban Market Drivers
……
25. Key Mergers And Acquisitions In The Apixaban Market
26. Top Apixaban Companies
27. Apixaban Market Opportunities And Strategies
28. Apixaban Market, Conclusions And Recommendations
29. Appendix

Discover Related Reports by The Business Research Company:
Automotive Centre Console Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/automotive-centre-console-global-market-report

Automotive Chassis Dynamometer Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/automotive-chassis-dynamometer-global-market-report

Automotive Micro Motor Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/automotive-micro-motor-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

 

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Apixaban Global Market Report 2024, the apixaban market is expected to show significant growth in the forecast period.

Current Market Dynamics

• Market Growth: The apixaban market has experienced robust growth in recent years. From a size of $2.69 billion in 2023, it is projected to rise to $2.92 billion in 2024. This represents a compound annual growth rate (CAGR) of 8.7%.
• Historical Drivers: This growth can be attributed to several factors including increased incidence of atrial fibrillation, an aging population, regulatory approvals, favorable clinical outcomes, and a shift from warfarin to novel oral anticoagulants (NOACs).

Future Outlook

• Projected Growth: The market is expected to grow significantly in the coming years, reaching $4.12 billion by 2028, with a CAGR of 9.0%.
• Forecast Drivers: This anticipated growth is driven by the continued incidence of cardiovascular diseases, higher awareness and diagnosis rates, expansion into emerging markets, an aging global population, and changes in health policies and reimbursements. Major trends include advancements in drug delivery systems, increased research and development, innovation and collaborations, FDA approvals, and the rise of digital health and telemedicine.

View More On The Apixaban Market Report 2024 – https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report

Impact of Cardiovascular Disease Prevalence

• Rising Cardiovascular Disease Rates: Cardiovascular diseases, including coronary artery disease, stroke, and heart failure, are on the rise due to factors like sedentary lifestyles, poor diet, tobacco use, obesity, high blood pressure, diabetes, and an aging population.
• Role of Apixaban: Apixaban is critical in managing cardiovascular conditions by reducing the risk of blood clots, which helps prevent strokes, deep vein thrombosis, and pulmonary embolism. The American Heart Association reported 931,578 deaths from cardiovascular diseases in January 2024, underscoring the increasing demand for effective treatments like apixaban.

Major Companies and Market Players

• Key Players: Major companies in the apixaban market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, and others.
• Focus Areas: These companies are advancing the market through innovation in drug development, including the introduction of generic versions of apixaban to increase affordability and access.

Rise of Generic Apixaban

• Increased Accessibility: The launch of generic apixaban versions is expanding access and affordability for patients. For instance, Tiefenbacher Pharmaceuticals introduced a generic form in Canada in October 2022. This move is set to enhance accessibility and provide cost savings in global healthcare systems.
• Product Availability: The generic versions include 2.5 mg and 5 mg tablets and are used for a range of thrombotic disorders including stroke prevention in atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism.

Strategic Acquisitions and Market Expansion

• SK Capital Partners Acquisition: In September 2022, SK Capital Partners acquired Apotex Pharmaceutical Holdings Inc., a Canadian company specializing in apixaban. This acquisition is expected to significantly impact drug manufacturing, distribution, and research.
• Pharmaceutical Segmentation: The apixaban market is segmented by dosage form (capsules, tablets), application (deep vein thrombosis, pulmonary embolism), and end-users (hospitals, homecare, specialty clinics).

Regional Insights

• Regional Market: North America was the largest market for apixaban in 2023. Looking ahead, the Asia-Pacific region is anticipated to be the fastest-growing area due to increasing healthcare investments and rising awareness.

The apixaban market is set for considerable growth, driven by a combination of rising cardiovascular disease prevalence, regulatory advancements, and market expansions. With innovations in drug delivery and the rise of generics, the landscape for apixaban continues to evolve, offering promising prospects for patients and healthcare systems alike.

Request A Sample Of The Global Apixaban Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=15979&type=smp